The impact of the number of prior androgen receptor pathway inhibitors before cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer
PSA response, PFS, and OS after CAZ administration did not significantly differ based on the number of prior ARPIs. CAZ efficacy appears consistent regardless of the number of prior ARPI sequences.
Authors
- Yuki Masuo (ORCID: https://orcid.org/0009-0007-3515-173X)
- Junichi Ikeda (ORCID: https://orcid.org/0000-0002-0797-8525)
- Hisanori Taniguchi (ORCID: https://orcid.org/0000-0002-7404-0369)
- Hidefumi Kinoshita (ORCID: https://orcid.org/0000-0002-6481-1967)
Institutions
- Kansai Medical University (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-02-23
- DOI
- https://doi.org/10.1093/jjco/hyaf034
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00